Review





Similar Products

droplet microarray dma slides  (Aquarray GmbH)
90
Aquarray GmbH droplet microarray dma slides
Droplet Microarray Dma Slides, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/droplet+microarray+(dma)+slides/droplet+microarray/pm37981010-231-1-8
Average 90 stars, based on 1 article reviews
droplet microarray dma slides - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
droplet microarray (dma) slides  (Aquarray GmbH)
90
Aquarray GmbH droplet microarray (dma) slides
Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
Droplet Microarray (Dma) Slides, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/droplet+microarray+(dma)+slides/droplet+microarray/pmc11469062-181-1-8
Average 90 stars, based on 1 article reviews
droplet microarray (dma) slides - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
droplet-microarray (dma) slides (1 × spots)  (Aquarray GmbH)
90
Aquarray GmbH droplet-microarray (dma) slides (1 × spots)
Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
Droplet Microarray (Dma) Slides (1 × Spots), supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/droplet+microarray+(dma)+slides/droplet+microarray/pm33325613-172-1-13
Average 90 stars, based on 1 article reviews
droplet-microarray (dma) slides (1 × spots) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
droplet-microarray (dma) slides × spots  (Aquarray GmbH)
90
Aquarray GmbH droplet-microarray (dma) slides × spots
Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
Droplet Microarray (Dma) Slides × Spots, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/droplet+microarray+(dma)+slides/droplet+microarray/pmc11469186-9-0-12
Average 90 stars, based on 1 article reviews
droplet-microarray (dma) slides × spots - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Workflow for high‐throughput drug screening and hit validation. The droplet microarray chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.

Journal: Advanced Healthcare Materials

Article Title: Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip

doi: 10.1002/adhm.202300591

Figure Lengend Snippet: Workflow for high‐throughput drug screening and hit validation. The droplet microarray chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.

Article Snippet: The droplet microarray (DMA) slides were purchased from Aquarray GmbH (catalog, IR0050241542, Eggenstein‐Leopoldshafen, Germany).

Techniques: High Throughput Screening Assay, Drug discovery, Biomarker Discovery, Microarray, Western Blot, Mass Spectrometry